Welcome to our dedicated page for Akero Therapeutics news (Ticker: AKRO), a resource for investors and traders seeking the latest updates and insights on Akero Therapeutics stock.
Akero Therapeutics, Inc. develops clinical-stage therapies for serious metabolic diseases, including metabolic dysfunction-associated steatohepatitis (MASH). Its lead product candidate, efruxifermin (EFX), is engineered to mimic the biological activity profile of native FGF21 and is being developed for MASH and related liver-disease settings, including pre-cirrhotic disease and compensated cirrhosis.
Akero news commonly covers clinical analyses from the HARMONY and SYMMETRY studies, updates tied to the SYNCHRONY development program, medical-meeting presentations, peer-reviewed publications, business updates, financial results and healthcare conference appearances. Recurring disclosures focus on fibrosis, MASH resolution, non-invasive markers of liver injury, insulin sensitivity, lipoprotein measures and the company’s clinical and capital-allocation activities.
Akero Therapeutics (NASDAQ: AKRO) presented new analyses from 96-week Phase 2b SYMMETRY and HARMONY trials of efruxifermin at AASLD 2025 (Nov 7-11, 2025). Post-hoc and AI-assisted digital pathology analyses corroborated prior conventional-pathology findings, reporting antifibrotic activity, reductions in total fibrosis and septa area, and statistically significant improvements in noninvasive measures linked to lower risk of liver-related events and clinically significant portal hypertension (CSPH) in compensated cirrhosis (F4c).
Four presentations (two oral, two posters) detail these results and timing: SYMMETRY and HARMONY data are being further validated in the company’s ongoing Phase 3 program.
Akero Therapeutics (Nasdaq: AKRO) agreed to be acquired by Novo Nordisk for up to $5.2 billion in cash on Oct 9, 2025. Shareholders will receive $54.00 per share in cash at closing plus a non-transferable CVR entitling holders to $6.00 per share if efruxifermin (EFX) receives full U.S. approval for compensated cirrhosis due to MASH by June 30, 2031.
The upfront cash equals ~$4.7 billion (a 19% premium to Akero 30-day VWAP and 42%+ premium to the May 19, 2025 closing price). Combined upfront and CVR represent a ~$5.2 billion equity value (a 32% premium to 30-day VWAP and 57%+ premium to May 19, 2025 close). Transaction approved by Akero board; expected to close around year-end pending shareholder and regulatory approvals.
Akero Therapeutics (NASDAQ: AKRO) announced two oral presentations and one poster at the 76th AASLD The Liver Meeting® 2025 in Washington, DC, Nov 7-11, 2025. Presentations will report 96-week data for efruxifermin (EFX) from the Phase 2b SYMMETRY study in compensated cirrhosis (F4c) due to MASH and AI-powered histology results from the Phase 2b HARMONY study in pre-cirrhotic (F2-F3) MASH.
Oral sessions are scheduled Nov 9, 2025 at 12:00 PM ET and 2:45 PM ET; the poster session is Nov 10, 2025 from 11:30 AM-12:30 PM ET.
Akero Therapeutics (NASDAQ:AKRO), a clinical-stage biotechnology company focused on developing treatments for serious metabolic diseases, has announced its participation in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference.
The presentation is scheduled for September 8, 2025, at 10:45 a.m. E.T. in New York. Investors can access the live webcast through Akero's investor relations website, with an archived replay available after the event.
Akero Therapeutics (Nasdaq: AKRO) published 96-week results from its Phase 2b HARMONY trial in The Lancet, evaluating efruxifermin (EFX) in patients with pre-cirrhotic MASH. The trial demonstrated significant efficacy with 49% of patients receiving 50mg EFX achieving at least one stage fibrosis improvement compared to 19% for placebo.
Key findings include 40% and 37% of patients achieving MASH resolution in the 28mg and 50mg groups respectively, versus 19% for placebo. The composite endpoint of MASH resolution and fibrosis improvement was met by 35% and 28% of participants in the 50mg and 28mg groups. Notably, 92% of week 24 responders maintained their response at week 96.
EFX was generally well-tolerated, with mainly mild to moderate gastrointestinal events reported. The results support EFX's potential to reduce disease progression in MASH patients.
Akero Therapeutics (Nasdaq: AKRO) reported significant progress in its clinical programs for EFX, a potential first- and best-in-class therapy for MASH (Metabolic dysfunction-Associated SteatoHepatitis). The company's 96-Week Phase 2b SYMMETRY trial results were published in the New England Journal of Medicine, demonstrating statistically significant reversal of compensated cirrhosis in MASH patients.
At EASL 2025, three presentations highlighted EFX's anti-fibrotic activity across all MASH stages. The data showed promising results in high-risk patient subgroups, including those with cryptogenic cirrhosis and type 2 diabetes. New analyses from the HARMONY study confirmed consistent fibrosis improvement in pre-cirrhotic MASH patients using both conventional and AI-based analysis methods.
Financially, Akero reported $1.09 billion in cash and equivalents as of June 30, 2025, expected to fund operations into 2028. Q2 operating expenses increased to $80.9 million, up from $65.7 million in the previous year, primarily due to ongoing Phase 3 trials.
Akero Therapeutics (Nasdaq: AKRO), a clinical-stage biotechnology company focused on developing treatments for serious metabolic diseases, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's management will deliver a presentation on Wednesday, June 4, 2025, at 8:45 a.m. Pacific Time. Investors and interested parties can access the live webcast through Akero's investor relations website section at www.akerotx.com, with an archived replay available after the event.